- Home
- LPCV vs OBIO Comparison
LPCV vs OBIO Comparison
Compare LPCV & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPCV | OBIO |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.5M | 246.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPCV | OBIO |
|---|---|---|
| Price | $9.99 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 3.6K | ★ 121.6K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $9.89 | $2.20 |
| 52 Week High | $10.03 | $5.42 |
Technical Indicators
Market Signals| Indicator | LPCV | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 41.49 |
| Support Level | $9.89 | $4.02 |
| Resistance Level | $10.03 | $4.17 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 80.00 | 12.59 |
Price Performance
Historical ComparisonAbout LPCV Launchpad Cadenza Acquisition Corp I Class A Ordinary Share
Launchpad Cadenza Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.